Facial Plast Surg 2018; 34(01): 009-013
DOI: 10.1055/s-0037-1617420
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Use of 5-Fluorouracil for Management of the Thick-Skinned Nose

Leslie E. Irvine
1   Santa Barbara Plastic Surgery Center, Santa Barbara, California
,
Paul S. Nassif
2   Department of Otolaryngology, Head and Neck Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California
3   Private Practice, Nassif MD Plastic Surgery, Beverly Hills, California
› Author Affiliations
Further Information

Publication History

Publication Date:
06 February 2018 (online)

Abstract

Patients with a thick nasal skin and soft tissue envelope can have unpredictable results and irregular scarring after rhinoplasty surgery. These patients typically have sebaceous tissue over the nasal tip and are particularly susceptible to soft tissue polly beak formation and excess scar tissue in the radix, tip, and septum. Targeted injections of 5-fluorouracil alone or mixed with low concentrations of steroid can be useful to prevent and treat excess postoperative scar tissue deposition. Ideally, four to six injections are performed every 1 to 4 weeks beginning 1 week postoperatively. The injections are most beneficial when performed within the first 3 months after surgery. Even a single injection may improve outcomes with minimal side effects.

 
  • References

  • 1 Botti G. Thick skin and cosmetic surgery of the nasal tip: how to avoid the cutaneous polly beak. Aesthetic Plast Surg 1996; 20 (05) 421-427
  • 2 Yoshioka A, Tanaka S, Hiraoka O. , et al. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 1987; 262 (17) 8235-8241
  • 3 Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3 (05) 330-338
  • 4 Wendling J, Marchand A, Mauviel A, Verrecchia F. 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol 2003; 64 (03) 707-713
  • 5 de Waard JW, de Man BM, Wobbes T, van der Linden CJ, Hendriks T. Inhibition of fibroblast collagen synthesis and proliferation by levamisole and 5-fluorouracil. Eur J Cancer 1998; 34 (01) 162-167
  • 6 Huang L, Cai YJ, Lung I, Leung BC, Burd A. A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro. J Plast Reconstr Aesthet Surg 2013; 66 (09) e251-e259
  • 7 Gressel MG, Parrish II RK, Folberg R. 5-fluorouracil and glaucoma filtering surgery: I. An animal model. Ophthalmology 1984; 91 (04) 378-383
  • 8 Skuta GL, Assil K, Parrish II RK, Folberg R, Weinreb RN. Filtering surgery in owl monkeys treated with the antimetabolite 5-fluorouridine 5′-monophosphate entrapped in multivesicular liposomes. Am J Ophthalmol 1987; 103 (05) 714-716
  • 9 Yoo DB, Azizzadeh B, Massry GG. Injectable 5-FU with or without added steroid in periorbital skin grafting: initial observations. Ophthal Plast Reconstr Surg 2015; 31 (02) 122-126
  • 10 Haurani MJ, Foreman K, Yang JJ, Siddiqui A. 5-Fluorouracil treatment of problematic scars. Plast Reconstr Surg 2009; 123 (01) 139-148 , discussion 149–151
  • 11 Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg 1999; 25 (03) 224-232
  • 12 Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 2002; 138 (09) 1149-1155
  • 13 Kontochristopoulos G, Stefanaki C, Panagiotopoulos A. , et al. Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. J Am Acad Dermatol 2005; 52 (3 Pt 1): 474-479
  • 14 Ren Y, Zhou X, Wei Z, Lin W, Fan B, Feng S. Efficacy and safety of triamcinolone acetonide alone and in combination with 5-fluorouracil for treating hypertrophic scars and keloids: a systematic review and meta-analysis. Int Wound J 2017; 14 (03) 480-487
  • 15 Gupta S, Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. Dermatology 2002; 204 (02) 130-132
  • 16 Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg 2004; 30 (01) 54-56 , discussion 56–57
  • 17 Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg 2006; 32 (07) 907-915
  • 18 Uppal RS, Khan U, Kakar S, Talas G, Chapman P, McGrouther AD. The effects of a single dose of 5-fluorouracil on keloid scars: a clinical trial of timed wound irrigation after extralesional excision. Plast Reconstr Surg 2001; 108 (05) 1218-1224
  • 19 Davison SP, Dayan JH, Clemens MW, Sonni S, Wang A, Crane A. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. Aesthet Surg J 2009; 29 (01) 40-46
  • 20 Apikian M, Goodman G. Intralesional 5-fluorouracil in the treatment of keloid scars. Australas J Dermatol 2004; 45 (02) 140-143
  • 21 Kafka M, Collins V, Kamolz LP, Rappl T, Branski LK, Wurzer P. Evidence of invasive and noninvasive treatment modalities for hypertrophic scars: A systematic review. Wound Repair Regen 2017; 25 (01) 139-144
  • 22 Shin JY, Kim JS. Could 5- fluorouracil or triamcinolone be an effective treatment option for keloid after surgical excision? A meta-analysis. J Oral Maxillofac Surg 2016; 74 (05) 1055-1060
  • 23 Ehrlich HP, Desmoulière A, Diegelmann RF. , et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol 1994; 145 (01) 105-113
  • 24 Uitto J, Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 2000; 24 (Suppl. 01) S60-S69
  • 25 Nikkhah D, Abood A, Watt D. Cicatricial ectropion: a complication of topical 5-fluorouracil. J Plast Reconstr Aesthet Surg 2012; 65 (01) e9-e10
  • 26 Tsui M, Tajirian A. Cicatricial ectropion with topical 5% fluorouracil cream. Dermatol Surg 2016; 42 (08) 1005-1006
  • 27 Hecker D, Hacker SM, Ramos-Caro FA, Flowers FP. Temporary ectropion due to topical fluorouracil. Cutis 1994; 53 (03) 137-138
  • 28 Lewis JE. Temporary ectropion due to topical fluorouracil. Int J Dermatol 1997; 36 (01) 79
  • 29 Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. Dermatol Surg 2012; 38 (01) 104-109
  • 30 Rees TD. An aid to the treatment of supratip swelling after rhinoplasty. Laryngoscope 1971; 81 (02) 308-311
  • 31 Guyuron B, DeLuca L, Lash R. Supratip deformity: a closer look. Plast Reconstr Surg 2000; 105 (03) 1140-1151 , discussion 1152–1153
  • 32 Hanasono MM, Kridel RW, Pastorek NJ, Glasgold MJ, Koch RJ. Correction of the soft tissue pollybeak using triamcinolone injection. Arch Facial Plast Surg 2002; 4 (01) 26-30 , discussion 31
  • 33 Park P, Jin HR. Diced cartilage in fascia for major nasal dorsal augmentation in Asians: a review of 15 consecutive cases. Aesthetic Plast Surg 2016; 40 (06) 832-839
  • 34 Mahé E, Camblin J, Micheli Pelegrini V. Injections of triamcinolone acetonide in the treatment of parrot beak [in French]. Ann Otolaryngol Chir Cervicofac 1974; 91 (12) 695-703
  • 35 Mahe E, Camblin J, Pelligrini VM. Treatment of postoperative Corbin's beak using repeated local triamcinolone acetonide injections [in French]. Ann Chir Plast 1975; 20 (01) 79-86
  • 36 Koh WL, Lim SP. Dramatic hyperpigmentation of keloids after intralesional triamcinolone acetonide injection. Dermatol Online J 2015; 21 (05) 13030/qt4dg9h1qr
  • 37 Tang YW. Intra- and postoperative steroid injections for keloids and hypertrophic scars. Br J Plast Surg 1992; 45 (05) 371-373
  • 38 Shafir R, Cohen M, Gur E. Blindness as a complication of subcutaneous nasal steroid injection. Plast Reconstr Surg 1999; 104 (04) 1180-1182 , discussion 1183–1184